Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Maximilian Kordes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5715-0881; OpenAlex author ID A5033394384. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2024.100070↗
  2. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal ad… Co-author DOI 10.1016/j.pan.2022.04.007↗
  3. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33464↗
  4. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. First author DOI 10.1002/jev2.12142↗
  5. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Co-author DOI 10.1038/s41416-021-01301-4↗
  6. Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.21.00024↗
  7. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  8. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  9. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Co-author DOI 10.3390/cancers12113234↗
  10. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. Co-author DOI 10.3390/jcm9113720↗
  11. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Co-author DOI 10.3390/cancers11091326↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias J. Löhr · 10 shared papers, 2019–2024 · strength 1.34
  2. Poya Ghorbani · 3 shared papers, 2020–2024 · strength 0.46
  3. Maria Gustafsson Liljefors · 3 shared papers, 2019–2024 · strength 0.46
  4. Carlos Fernández Moro · 2 shared papers, 2021–2024 · strength 0.32
  5. Raffaella Pozzi Mucelli · 2 shared papers, 2020–2024 · strength 0.28
  6. Patrick Maisonneuve · 3 shared papers, 2020 · strength 0.26
  7. Jingru Yu · 2 shared papers, 2019–2021 · strength 0.24
  8. Lars G. Engstrand · 1 shared paper, 2021 · strength 0.19
  9. Marco Del Chiaro · 1 shared paper, 2024 · strength 0.18
  10. Linnéa Malgerud · 1 shared paper, 2024 · strength 0.18
  11. Jan‐Erik Frödin · 1 shared paper, 2024 · strength 0.18
  12. Mikael Björnstedt · 1 shared paper, 2024 · strength 0.18
  13. Nikolaos Kartalis · 1 shared paper, 2024 · strength 0.18
  14. Marcus Holmberg · 1 shared paper, 2022 · strength 0.17
  15. Maria Liljefors · 1 shared paper, 2022 · strength 0.17
  16. Ernesto Sparrelid · 1 shared paper, 2022 · strength 0.17
  17. Stefan Linder · 1 shared paper, 2022 · strength 0.17
  18. Giuseppe Malleo · 2 shared papers, 2020 · strength 0.16
  19. Michael Haas · 2 shared papers, 2020 · strength 0.16
  20. Marko Damm · 2 shared papers, 2020 · strength 0.16
  21. John A. G. Moir · 2 shared papers, 2020 · strength 0.16
  22. Stephan Krüger · 2 shared papers, 2020 · strength 0.16
  23. Maximilian Weniger · 2 shared papers, 2020 · strength 0.16
  24. Laura Maggino · 2 shared papers, 2020 · strength 0.16
  25. Stephan Schorn · 2 shared papers, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.